Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK8 | P45983 | 18/20 | 0.67 |
| ▸ | MAPK9 | P45984 | 18/20 | 0.67 |
| ▸ | MAPK10 | P53779 | 17/20 | 0.67 |
| ▸ | CDK2 | P24941 | 3/20 | 0.50 |
| ▸ | CCNE1 | P24864 | 2/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.50 |
| ▸ | GSK3B | P49841 | 2/20 | 0.47 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.47 |
| ▸ | JUN | P05412 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5096260 | 1.00 | MAPK8 (0.67) | MAPK8MAPK9MAPK10CDK2CCNE1 | |
| SCHEMBL5090282 | 0.85 | MAPK8 (0.77) | MAPK8MAPK9MAPK10CDK2CCNE1 | |
| SCHEMBL3809101 | 0.85 | MAPK8 (0.77) | MAPK8MAPK9MAPK10CDK2CCNE1 | |
| SCHEMBL5093797 | 0.84 | MAPK8 (0.66) | MAPK8MAPK9MAPK10CDK2CCNE1 | |
| SCHEMBL8201467 | 0.84 | MAPK8 (0.71) | MAPK8MAPK9MAPK10CDK2CCNE1 | |
| SCHEMBL3810122 | 0.84 | MAPK8 (0.71) | MAPK8MAPK9MAPK10CDK2CCNE1 | |
| SCHEMBL5102470 | 0.84 | MAPK8 (0.71) | MAPK8MAPK9MAPK10CDK2CCNE1 | |
| SCHEMBL5090618 | 0.82 | MAPK8 (0.68) | MAPK8MAPK9MAPK10CDK2CCNE1 | |
| SCHEMBL5093787 | 0.82 | MAPK8 (0.68) | MAPK8MAPK9MAPK10CDK2CCNE1 | |
| SCHEMBL5102745 | 0.82 | MAPK8 (0.63) | MAPK8MAPK9MAPK10CDK2CCNE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8399462-B2 | 4-[4-(4-benzyloxy-indol-1-yl)-pyrimidin-2-ylamino]-cyclohexanol; autoimmune, inflammatory, metabolic, neurological diseases as well as cancer and pain | ROCHE PALO ALTO LLC (US) | 2013-03-19 | — | — | US | disclosed |
| US-20080146565-A1 | JNK modulators | ROCHE PALO ALTO LLC | 2008-06-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080146565-A1 | JNK modulators | MAPKAPK2, MAPKAPK3, MAP3K10 | MAPK8 40/4885MAPK9 43/4885MAPK10 31/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.